October 7, 2025 — The TB Alliance projects that, in their first 15 years of approval (by 2034), the six-month, all-oral BPaL/M regimens for the treatment of drug-resistant TB (DR-TB) will be used to treat 2,037,988 people with DR-TB, saving 191,222 additional lives. These regimens also reduce treatment length, complexity, side effects, and pill burden improve the patients’ treatment experiences for all who receive six-month, all-oral DR-TB therapy. Read more in the TB Alliance press release.
Please note that the “Posted on” date reflects the date that the news archives were transferred to NTCA’s redesigned website, not the date of the original news item.
